<status value="active"/> <experimental value="false"/> <date value="2026-03-17T21:02:03.8104715+00:00"/> <publisher value="HL7 International / Terminology Infrastructure"/> <contact> <name value="HL7 International / Terminology Infrastructure"/> <telecom> <system value="url"/> <value value="http://www.hl7.org/Special/committees/Vocab"/> </telecom> </contact> <description value="This cross-version ValueSet represents content from `http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution|2018-08-12` for use in FHIR R4B."/> <jurisdiction> <coding> <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/> <code value="001"/> <display value="World"/> </coding> </jurisdiction> <purpose value="This value set is part of the cross-version definitions generated to enable use of the value set `http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution|2018-08-12` as defined in FHIR R4 in FHIR R4B. The source value set is bound to the following FHIR R4 elements: * Note that all concepts are included in this cross-version definition because no concepts have compatible representations Following are the generation technical comments: FHIR ValueSet `http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution|2018-08-12`, defined in FHIR R4 does not have any mapping to FHIR R4B"/> <compose> <include> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <concept> <code value="BC"/> <display value="brand composition"/> </concept> <concept> <code value="E"/> <display value="equivalent"/> </concept> <concept> <code value="EC"/> <display value="equivalent composition"/> </concept> <concept> <code value="F"/> <display value="formulary"/> </concept> <concept> <code value="G"/> <display value="generic composition"/> </concept> <concept> <code value="N"/> <display value="none"/> </concept> <concept> <code value="TB"/> <display value="therapeutic brand"/> </concept> <concept> <code value="TE"/> <display value="therapeutic alternative"/> </concept> <concept> <code value="TG"/> <display value="therapeutic generic"/> </concept> <concept> <code value="_ActSubstanceAdminSubstitutionCode"/> <display value="ActSubstanceAdminSubstitutionCode"/> </concept> </include> </compose> <expansion> <timestamp value="2026-03-17T21:02:03.8104715+00:00"/> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="BC"/> <display value="brand composition"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="E"/> <display value="equivalent"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="EC"/> <display value="equivalent composition"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="F"/> <display value="formulary"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="G"/> <display value="generic composition"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="N"/> <display value="none"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="TB"/> <display value="therapeutic brand"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="TE"/> <display value="therapeutic alternative"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="TG"/> <display value="therapeutic generic"/> </contains> <contains> <system value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/> <version value="2018-08-12"/> <code value="_ActSubstanceAdminSubstitutionCode"/> <display value="ActSubstanceAdminSubstitutionCode"/> </contains> </expansion> </ValueSet>

Generated Narrative: ValueSet R4-v3-substanceAdminSubstitution-for-R4B

This value set expansion contains 10 concepts.

System	Version	Code	Display	Definition
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	BC	brand composition	Description: `Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven`
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	E	equivalent	Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	EC	equivalent composition	Description: `Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril`
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	F	formulary	Description: This substitution was performed or is permitted based on formulary guidelines.
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	G	generic composition	Description: Substitution occurred or is permitted between equivalent Generics but not Brands `Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)`
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	N	none	No substitution occurred or is permitted.
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	TB	therapeutic brand	Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics `Examples: Zantac for Tagamet`
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	TE	therapeutic alternative	Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. `Examples: ranitidine for Tagamet`
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	TG	therapeutic generic	Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands `Examples: Ranitidine for cimetidine`
`http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution`	2018-08-12	_ActSubstanceAdminSubstitutionCode	ActSubstanceAdminSubstitutionCode	Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.